Abstract
Mechanisms through which major risk factors accelerate diabetic angiopathy include low density lipoprotein (LDL) oxidation and advanced glycation end products (AGEs) formation. Lectin-like oxidized LDL receptor (LOX-1) is a newly identified vascular receptor for oxidized LDL (oxLDL) and AGEs. LOX-1 is up-regulated in vascular endothelium of diabetic animals and thus may be relevant to the development and progression of human diabetic vasculopathy. The mechanisms responsible for LOX-1 induction in diabetes remain unclear but appear to involve metabolic and inflammatory stimuli relevant to diabetes. Such factors may impact on LOX-1-mediated pro-atherogenic events, including endothelial dysfunction and plaque destabilization. Previous studies have shown that drugs commonly used in the treatment of type 2 diabetic patients, including statins and antidiabetic agents, inhibit endothelial LOX-1 expression. This review summarizes recent advances related to the role of LOX-1 in macrovascular diseases, its regulation by some derangements commonly found in diabetic patients and its modulation by vasculoprotective drugs.
Keywords: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), diabetes, endothelial dysfunction, inflammation, hyperglycemia, fatty acids
Cardiovascular & Hematological Disorders-Drug Targets
Title: Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1), a Relevant Target for Diabetic Vasculopathy?
Volume: 8 Issue: 3
Author(s): Genevieve Renier
Affiliation:
Keywords: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), diabetes, endothelial dysfunction, inflammation, hyperglycemia, fatty acids
Abstract: Mechanisms through which major risk factors accelerate diabetic angiopathy include low density lipoprotein (LDL) oxidation and advanced glycation end products (AGEs) formation. Lectin-like oxidized LDL receptor (LOX-1) is a newly identified vascular receptor for oxidized LDL (oxLDL) and AGEs. LOX-1 is up-regulated in vascular endothelium of diabetic animals and thus may be relevant to the development and progression of human diabetic vasculopathy. The mechanisms responsible for LOX-1 induction in diabetes remain unclear but appear to involve metabolic and inflammatory stimuli relevant to diabetes. Such factors may impact on LOX-1-mediated pro-atherogenic events, including endothelial dysfunction and plaque destabilization. Previous studies have shown that drugs commonly used in the treatment of type 2 diabetic patients, including statins and antidiabetic agents, inhibit endothelial LOX-1 expression. This review summarizes recent advances related to the role of LOX-1 in macrovascular diseases, its regulation by some derangements commonly found in diabetic patients and its modulation by vasculoprotective drugs.
Export Options
About this article
Cite this article as:
Renier Genevieve, Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1), a Relevant Target for Diabetic Vasculopathy?, Cardiovascular & Hematological Disorders-Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/187152908785849107
DOI https://dx.doi.org/10.2174/187152908785849107 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Leukocytes in Diabetic Retinopathy
Current Diabetes Reviews The Role of Alpha-lipoic Acid Supplementation in the Prevention of Diabetes Complications: A Comprehensive Review of Clinical Trials
Current Diabetes Reviews Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Review of Theoretical Studies for Prediction of Neurodegenerative Inhibitors
Mini-Reviews in Medicinal Chemistry The Protective Effect of Jatrorrhizine Against Oxidative Stress in Primary Rat Cortical Neurons
CNS & Neurological Disorders - Drug Targets Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Stroke Prevention: From Available Antiplatelet Drugs to Novel Molecular Targets
Current Drug Targets Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy Molecular Linkages Between Diabetes and Alzheimer's Disease: Current Scenario and Future Prospects
CNS & Neurological Disorders - Drug Targets Gene Regulation of Aldose-, Aldehyde- and a Renal Specific Oxido Reductase (RSOR) in the Pathobiology of Diabetes Mellitus
Current Medicinal Chemistry Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry Subject Index to Volume 1
Current Alzheimer Research Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Cerebrovascular Damage as a Cause for Alzheimers Disease
Current Neurovascular Research Candidate Susceptibility Genes in Alzheimers Disease Are at High Risk for Being Forgotten - They Dont Give Peace of Mind...
Current Drug Metabolism Pharmacological Inhibition of Platelet Reactivity. Clinical and Pharmacodynamic Effects
Current Vascular Pharmacology <i>Drosophila melanogaster</i> a Versatile Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#
Current Alzheimer Research